Clinical trials: Lipid Metabolism Disorders
Body Fat Disorder
DualSculpting the Abdomen Using CoolSculpting
Evaluate the safety and efficacy of abdominal DualSculpting with CoolAdvantage applicators.
- Trial name
- DSA (NCT02941146)
- Testing
- The ZELTIQ System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Hypercholesterolaemia
Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months.
- Trial name
- NCT01483950
- Where
- 14 sites in Bosnia and Herzegovina
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Dyslipidemias
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medical practice.
- Trial name
- TREZETE (NCT04862962)
- Testing
- Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
- Where
- Mexico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
High Blood Cholesterol
An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon
This was a multicenter survey of patients who were on lipid -lowering pharmacological treatment in 2 Levant countries namely Jordan and Lebanon.
- Trial name
- CEPHEUS (NCT01614561)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older
A prospective, open, observational study to confirm the lipid-lowering effect, changes in glucose metabolism, and safety after 6 months of administration of atostazet to hypercholesterolemic patients 65 years of age or older
- Trial name
- DW-EAZ-OS01 (NCT07489183)
- Where
- South Korea
- Volunteers
- 641 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Hypertriglyceridemia
Bioavailability of EPA and DHA From Two Dietary Supplements
The primary objective of this study is to test the effects of two different fish oil products containing DHA and EPA by comparing the omega-3 fatty acid levels in the blood.
- Trial name
- NCT01908374
- Testing
- DHA-rich fish oil versus Phospholipid-rich fish oil
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Arctic Nutrition AS
Diabetes in Adolescence, PreDiabetes
The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism
The aim of the study is to demonstrate that a daily supplementation of AP029 Mix: I) has a positive effect on reducing side effects of metformin, while enhancing the therapeutic effect of metformin; II) normalizes prediabetes…
- Trial name
- NCT05994586
- Testing
- AP029 mix
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- AronPharma Sp. z o. o.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Diabetes Mellitus
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and…
- Trial name
- PLANET 1 (NCT00296374)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 116 sites in United States, Argentina and 9 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Hypercholesterolemia and High Risk for Cardiovascular Events
A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
The primary objective is to evaluate the effect of 12 weeks of subcutaneous evolocumab every 2 weeks or every 4 weeks, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) when…
- Trial name
- AMG145 (NCT01652703)
- Testing
- Evolocumab
- Where
- 42 sites in Japan
- Volunteers
- 310 people
- Sponsor
- Amgen
Hypercholesterolemia, Coronary Heart Disease
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
The purpose of this study is to compare the effect of 8 weeks of treatment with Rosuvastatin with 8 weeks of treatment with Atorvastatin on low density lipoprotein cholesterol level in subjects with hypercholesterolemia and…
- Trial name
- POLARIS (NCT00653588)
- Testing
- Rosuvastatin, Atorvastatin
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.
- Trial name
- NCT02824003
- Testing
- ISIS-GCGRRx
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypercholesterolemia
Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Primary Objective: Injection Site Tolerability Secondary Objective: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01448304
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
This study will evaluate and compare the effectiveness of MK-0653 (Vytorin) to current standard treatment with other statins for the treatment of dyslipidemia in moderate, moderately-high and high-risk participants.
- Trial name
- VYCTORY (NCT01587235)
- Testing
- Ezetimibe/simvastatin, Other Statin
- Sponsor
- Organon and Co
Hypertriglyceridemia
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG).
- Trial name
- MUIR-3 (NCT06347133)
- Testing
- Plozasiran Injection
- Where
- 235 sites in United States, Argentina and 13 more
- Volunteers
- 1,456 people
- Sponsor
- Arrowhead Pharmaceuticals
Healthy Participants
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative…
- Trial name
- NCT07316608
- Testing
- Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Dyslipidemia
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
The objectives of this study is To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameters from baseline after 12 weeks of treatment.
- Trial name
- NCT01893515
- Testing
- PRC-4016
- Where
- 39 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pronova BioPharma
Body Fat Disorder
Effects on Cellulite Appearance
Evaluate the safety and feasibility effecting the appearance of cellulite on the thigh using CoolSculpting.
- Trial name
- EFC (NCT04876118)
- Testing
- The ZELTIQ System
- Where
- 6 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Elevated LDL Cholesterol
Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol
This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of…
- Trial name
- NCT01362218
- Testing
- Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril), Simvastatin, ramipril, acetylsalicylic acid
- Where
- Spain
- Volunteers
- 107 people
- Sponsor
- Ferrer Internacional S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.